Crucial Innovations' Losses Widen Amidst Zero Revenue, Soaring Liabilities

TL;DR

**Crucial Innovations is a pre-revenue penny stock with mounting debt and no clear path to profitability, making it a highly speculative gamble.**

AI Summary

Crucial Innovations Corp. reported no revenue for the three and nine months ended September 30, 2025, consistent with the prior year. The company experienced a net loss of $959,496 for the three months ended September 30, 2025, compared to a net loss of $523,819 in the same period of 2024, representing an 83.1% increase in loss. For the nine months ended September 30, 2025, the net loss was $5,836,580, a significant reduction from the $90,337,183 net loss in the prior year, primarily due to lower management and professional fees. Total assets increased substantially to $796,838 as of September 30, 2025, from $91,591 at December 31, 2024, driven by a $667,924 advance to a supplier and $67,951 in restricted cash. Total liabilities also surged to $4,289,264 from $1,871,473, largely due to a rise in accounts payable and accrued liabilities to $1,298,604 and an increase in amounts due to related parties to $2,186,942. The company's strategic outlook involves its medical cannabis business in the UK and Europe, through its acquisition of Ember Pharms (Pty) Ltd and its joint venture Crop Circle Dispensary Limited, though Crop Circle has had no business transactions since inception through September 30, 2025. Key risks include the company's accumulated deficit of $97,139,503 and its reliance on related party financing.

Why It Matters

This filing reveals Crucial Innovations Corp. is a pre-revenue company with significant financial instability, operating with an accumulated deficit of over $97 million. For investors, this signals extreme risk, as the company has yet to generate any sales despite its pivot to medical cannabis. The substantial increase in liabilities, particularly to related parties, raises concerns about financial independence and potential conflicts of interest. Employees and customers face uncertainty given the lack of operational revenue and the company's reliance on external financing. In the competitive medical cannabis market, Crucial Innovations' inability to execute its business plan and generate revenue puts it at a severe disadvantage against established players.

Risk Assessment

Risk Level: high — The company reported zero revenue for both the three and nine months ended September 30, 2025, and an accumulated deficit of $97,139,503. Cash on hand is critically low at $317 as of September 30, 2025, while total liabilities increased to $4,289,264, indicating severe liquidity issues and a high risk of financial distress.

Analyst Insight

Investors should avoid Crucial Innovations Corp. given its pre-revenue status, substantial accumulated deficit, and increasing liabilities. The company's reliance on related party financing and minimal cash reserves suggest a high probability of further dilution or financial collapse. This is a speculative venture with no clear path to profitability.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

$796,838

total Debt

$4,289,264

net Income

$(5,836,580)

eps

N/A

gross Margin

N/A

cash Position

$317

revenue Growth

0.0%

Revenue Breakdown

Key Numbers

• $0 — Revenue (for three and nine months ended September 30, 2025, indicating no operational sales)
• $(959,496) — Net Loss (3 months) (for the three months ended September 30, 2025, an 83.1% increase from prior year)
• $(5,836,580) — Net Loss (9 months) (for the nine months ended September 30, 2025, a significant reduction from $90.3M prior year)
• $796,838 — Total Assets (as of September 30, 2025, up from $91,591 at December 31, 2024)
• $4,289,264 — Total Liabilities (as of September 30, 2025, up from $1,871,473 at December 31, 2024)
• $(97,139,503) — Accumulated Deficit (as of September 30, 2025, highlighting severe historical losses)
• $317 — Cash (as of September 30, 2025, critically low for operations)
• $2,186,942 — Due to related parties (as of September 30, 2025, indicating reliance on insider financing)
• 418,694,150 — Common Shares Outstanding (as of September 30, 2025, indicating significant share count)

Key Players & Entities

• Crucial Innovations Corp. (company) — registrant
• Ember Pharms (Pty) Ltd (company) — acquired medical cannabis grower
• Inspire Pharmacy (company) — UK medical cannabis distributor and joint venture partner
• Crop Circle Dispensary Limited (company) — joint venture entity with Inspire Pharmacy
• Tomanic Trading (Pty) Ltd (company) — South African medical cannabis supplier
• Securities and Exchange Commission (regulator) — filing oversight
• Nevada (location) — state of incorporation
• United Kingdom (location) — primary market for medical cannabis business

FAQ

Risk Factors

• Accumulated Deficit [high — financial]: The company has a substantial accumulated deficit of $97,139,503 as of September 30, 2025. This indicates significant historical losses and raises concerns about the company's long-term viability and ability to achieve profitability.
• Reliance on Related Party Financing [high — financial]: As of September 30, 2025, amounts due to related parties totaled $2,186,942, representing a significant portion of total liabilities. This reliance on insider financing can create conflicts of interest and may not be sustainable.
• Lack of Revenue Generation [high — operational]: Crucial Innovations Corp. reported zero revenue for the three and nine months ended September 30, 2025. This lack of sales indicates a failure to commercialize its products or services, posing a significant operational risk.
• Uncertainty in Strategic Ventures [medium — operational]: The company's strategic outlook relies on its medical cannabis business through Ember Pharms (Pty) Ltd and a joint venture with Crop Circle Dispensary Limited. However, Crop Circle has had no business transactions since inception through September 30, 2025, casting doubt on the success of this venture.
• Increasing Net Loss [high — financial]: The net loss for the three months ended September 30, 2025, was $959,496, an 83.1% increase from the $523,819 loss in the prior year. This trend, despite a reduction in overall nine-month losses, indicates worsening short-term operational performance.
• Significant Increase in Liabilities [high — financial]: Total liabilities surged to $4,289,264 as of September 30, 2025, from $1,871,473 at December 31, 2024. This rapid increase, driven by payables and related party debt, strains the company's financial position.
• Low Cash Position [high — financial]: The company's cash balance was critically low at $317 as of September 30, 2025. This severely limits its ability to fund ongoing operations and meet short-term obligations.
• Substantial Advance to Supplier [medium — financial]: An advance of $667,924 to a supplier significantly increased total assets. The nature and recoverability of this advance are unclear and represent a potential financial risk if the supplier fails to deliver.

Industry Context

Crucial Innovations Corp. is operating within the emerging medical cannabis sector, primarily targeting the UK and European markets. This industry is characterized by evolving regulatory landscapes, significant growth potential, and intense competition from both established players and new entrants. Success often hinges on navigating complex legal frameworks, securing supply chains, and effective market penetration.

Regulatory Implications

The company's operations in the medical cannabis sector are subject to stringent and evolving regulations in the UK and Europe. Changes in legislation, licensing requirements, or compliance standards could significantly impact its ability to operate and generate revenue. Failure to adhere to these regulations could result in fines, operational shutdowns, or reputational damage.

What Investors Should Do

1. Monitor progress of strategic ventures
2. Scrutinize related party transactions
3. Assess the recoverability of supplier advance
4. Evaluate the path to profitability

Key Dates

• 2025-09-30: Quarterly Financial Reporting — Reported zero revenue and an increased net loss for the quarter, highlighting ongoing operational challenges and a worsening short-term financial position.
• 2025-09-30: Balance Sheet Date — Showcased a significant increase in assets and liabilities, driven by supplier advances and related party debt, indicating substantial changes in financial structure.
• 2024-12-31: Prior Year End Balance Sheet — Provides a baseline for comparison, showing a much smaller asset and liability base prior to the recent significant increases.

Glossary

Accumulated deficit

The total net losses of a company over its lifetime that have not been offset by net income. (Indicates the company's historical unprofitability and the significant losses it has incurred to date, totaling $97,139,503.)

Due to related parties

Amounts owed by the company to its directors, officers, significant shareholders, or affiliated companies. (Highlights the company's reliance on financing from individuals or entities closely connected to management, which can pose risks.)

Restricted cash

Cash that is not available for general use by the company because it is pledged as collateral or otherwise restricted by contractual agreements. (Represents cash set aside for specific purposes, reducing the amount of readily available funds for operations.)

Advances to supplier

Payments made to a supplier before goods or services are delivered. (A significant asset on the balance sheet ($667,924), representing a potential risk if the supplier does not fulfill its obligations.)

Convertible notes

Debt instruments that can be converted into shares of the issuing company's stock. (Represents a new form of debt ($633,720) that could dilute existing shareholders if converted.)

Treasury stock

Shares of a company's own stock that it has repurchased from the open market. (Indicates the company has bought back 20,000,000 shares, which reduces total equity but can be used for various corporate purposes.)

Year-Over-Year Comparison

Compared to December 31, 2024, Crucial Innovations Corp. has seen a dramatic increase in both total assets (from $91,591 to $796,838) and total liabilities (from $1,871,473 to $4,289,264). This shift is largely due to a substantial advance to a supplier and increased related party debt. While the nine-month net loss has significantly decreased from $90,337,183 to $5,836,580, the three-month net loss has widened by 83.1% to $959,496, indicating a concerning short-term deterioration in operational performance. The company also faces new risks related to its substantial supplier advance and convertible notes.

Key Financial Figures

• $0.001 — hares of the registrant's common stock, $0.001 par value, outstanding, as of September
• $0 — 1,000,000,000 authorized; par value of $0.001, 418,694,150 shares and 381,320,798
• $299 — d cash at the end of period $ 68,268 $299 Supplemental cash flow information:
• $330,869 — uisition Ember Pharms (Pty) Ltd. $ — $330,869 Common stock issued for stock subscri
• $317 — ember 31, 2024. The Company had cash of $317 and $52,668, as of September 30, 2025,
• $52,668 — 2024. The Company had cash of $317 and $52,668, as of September 30, 2025, and December
• $250,000 — ore than the federally insured limit of $250,000 per institution. The Company has not ex

Filing Documents

• f10q_cinv09302025.htm (10-Q) — 624KB
• ex311_302ceocertification.htm (EX-31.1) — 7KB
• ex312_302cfocertification.htm (EX-31.2) — 7KB
• ex321_906ceocertification.htm (EX-32.1) — 4KB
• ex322_906cfocertification.htm (EX-32.2) — 5KB
• 0001766016-25-000004.txt ( ) — 649KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Condensed Consolidated Financial Statements (unaudited)

Item 1. Condensed Consolidated Financial Statements (unaudited) 3 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Operations and Comprehensive Loss 4 Condensed Consolidated Statements of Stockholders' Deficit 5 Condensed Consolidated Statements of Cash Flows 7 Notes to Condensed Consolidated Financial Statements 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 23

Quantitative and Qualitative Disclosures about Market Risk

Item 3. Quantitative and Qualitative Disclosures about Market Risk 30

Controls and Procedures

Item 4. Controls and Procedures 30

OTHER INFORMATION

PART II. OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 31

Risk Factors

Item 1A. Risk Factors 31

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 31

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 31

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 32

Other Information

Item 5. Other Information 32

Exhibits

Item 6. Exhibits 32

SIGNATURES

SIGNATURES 33 2 Table of Contents

Financial Information

Part I. Financial Information

Consolidated Condensed Financial Statements (Unaudited)

Item 1. Consolidated Condensed Financial Statements (Unaudited) CRUCIAL INNOVATIONS CORP. AND ITS SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) September 30, December 31, 2025 2024 ASSETS Current Assets Cash $ 317 $ 52,668 VAT receivable 26,582 15,605 Prepaid expenses 6,130 12 Advances to supplier 667,924 — Other receivable 2,139 — Total Current Assets 703,092 68,285 Property and equipment, net 25,795 23,306 Restricted cash 67,951 — Total Assets $ 796,838 $ 91,591 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Current Liabilities Accounts payable and accrued liabilities $ 1,298,604 $ 784,788 Contract advances 102,988 33,942 Advances 67,010 — Due to related parties 2,186,942 1,052,743 Total Current Liabilities 3,655,544 1,871,473 Convertible notes 633,720 — Total Liabilities 4,289,264 1,871,473 Commitments and contingencies — — Stockholders' Deficit Preferred stock: 100,000,000 authorized; $0.001 par value, no shares issued and outstanding — — Common stock: 1,000,000,000 authorized; par value of $0.001, 418,694,150 shares and 381,320,798 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 418,694 381,321 Additional paid-in capital 93,331,613 89,117,267 Treasury stock , at cost : 20,000,000 shares (20,000 ) — Accumulated deficit (97,139,503 ) (91,302,923 ) Accumulated other comprehensive income (loss) (83,230 ) 24,453 Total Stockholders' Deficit (3,492,426 ) (1,779,882 ) Total Liabilities and Stockholders' Deficit $ 796,838 $ 91,591 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 3 Table of Contents CRUCIAL INNOVATIONS CORP. AND ITS SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) For the For the Three Months Ended Nine Months Ended September 30, September 30, 2025

View Full Filing

View this 10-Q filing on SEC EDGAR